Metabolic commences phase IIb obesity drug trial

By Ruth Beran
Thursday, 20 October, 2005

Melbourne-based Metabolic Pharmaceuticals (ASX:MBP) has started recruiting subjects in a low dose phase IIb clinical trial of its obesity drug AOD9604.

The new phase IIb study, known as the "Options" study, will test three different daily doses -- tablets of 1mg, 0.5mg, 0.25mg AOD9604 active ingredient and placebo -- following analysis of results from last year's phase IIb study that suggested the optimal dosage of AOD9604 was potentially below the lowest dose of 1mg used in the trial.

The study will enrol 480 obese men and women at sixteen clinical trial sites in Australia located in Melbourne, Sydney, Wollongong, Adelaide, Brisbane, Perth and Canberra.

"Given the encouraging trial results to date and the potential of this drug there will no doubt be substantial local and international interest in this trial and we are very excited about is prospects," said Metabolic CEO Dr Roland Scollay in a statement.

Two sites have been granted ethics approval and the approval process is advanced at the other sites.

One site has begun recruiting patients and it is expected that within the next few weeks the first subject will be treated, and screening of candidates for enrolment into the study will begin.

The last subject is expected to complete the study in early 2007.

Related News

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd